4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
31.86 USD -11.18% Intraday chart for 4D Molecular Therapeutics, Inc. -5.74% +57.26%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis MT
Transcript : 4D Molecular Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium? 2024 CI
4d Molecular Therapeutics Insider Sold Shares Worth $737,788, According to a Recent SEC Filing MT
4D Molecular Therapeutics Launches $250 Million Stock Offering MT
4D Molecular Therapeutics Shares Surge on Positive Data From Phase 2 Study of Wet AMD Drug Candidate MT
Top Midday Gainers MT
BMO Capital Adjusts 4D Molecular Therapeutics' Price Target to $70 From $50, Keeps Outperform Rating MT
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes' RE
Powell Comments Dampen Near-Term Rate Cut Hopes, Stifling US Equity Futures Pre-Bell MT
RBC Raises PT on 4D Molecular Therapeutics to $35 From $25, Keeps Outperform Rating, Speculative Risk MT
Transcript : 4D Molecular Therapeutics, Inc. - Special Call
Top Premarket Gainers MT
4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150 CI
4D Molecular Therapeutics' Treatment Candidate for Cystic Fibrosis Gets FDA Rare Pediatric Disease Designation MT
4D Molecular Therapeutics Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease CI
4D Molecular Therapeutics, Inc. Announces Management Changes CI
4D Molecular Therapeutics Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates CI
4D Molecular Therapeutics and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases CI
4D Molecular Therapeutics, Arbor Biotechnologies Form Central Nervous System Disease Partnership MT
4D Molecular Shares Rise on FDA Designation for Wet AMD Drug DJ
4D Molecular Therapeutics Shares Rise as Wet AMD Treatment Candidate Gets FDA's RMAT Designation MT
4D Molecular Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD CI
4D Molecular Therapeutics' Q3 Loss Narrows, Revenue Jumps MT
Chart 4D Molecular Therapeutics, Inc.
More charts
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
35.87 USD
Average target price
52.12 USD
Spread / Average Target
+45.32%
Consensus
  1. Stock
  2. Equities
  3. Stock 4D Molecular Therapeutics, Inc. - Nasdaq
  4. News 4D Molecular Therapeutics, Inc.
  5. HC Wainwright Starts 4D Molecular Therapeutics at Buy With $36 Price Target